{"issuance_frequency":"","notes_translated":{"fr":"es rapports périodiques d'évaluation des avantages et des risques (RPEAR) décrits dans la présente ligne directrice sont destinés à devenir la norme générale pour l'évaluation périodiques des avantages et des risques des produits commercialisés (y compris les médicaments approuvés qui font l'objet d'études complémentaires) dans les régions membres de l'ICH. La ligne directrice définit le format et le contenu recommandés d'un RPEAR et propose des points à prendre en considération en vue de rédiger et de présenter un RPEAR.","en":"The Periodic Benefit-Risk Evaluation Report (PBRER) described in this Guideline is intended to be a common standard for periodic benefit-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the International Conference on Harmonisation (ICH) regions. This Guideline defines the recommended format and content of a PBRER and provides an outline of points to be considered in its preparation and submission."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"8897d00d-e58b-48ac-876b-5db8a5ba1dcf","metadata_created":"2021-07-07T19:41:38.638723","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T19:41:38.638729","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Document d'orientation","rapport d'évaluation périodique bénéfice-risque","PBRER","International Conference on Harmonisation","ICH","Topic E2C(R2)","reporting sur les produits commercialisés"],"en":["Guidance document","periodic benefit-risk evaluation report","PBRER","International Conference on Harmonisation","ICH","Topic E2C(R2)","reporting on marketed products"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice - Rapport périodique d'évaluation des avantages et des risques (RPEAR) International Conference on Harmonisation (ICH) thème E2C(R2)","en":"Guidance Document - Periodic Benefit-Risk Evaluation Report (PBRER) International Conference on Harmonisation (ICH) Topic E2C(R2)"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"8897d00d-e58b-48ac-876b-5db8a5ba1dcf","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4d70ca31-8c14-4a08-876a-b42c2145a424","related_relationship":"","name_translated":{"fr":"Ligne directrice - Rapport périodique d'évaluation des avantages et des risques (RPEAR) International Conference on Harmonisation (ICH) thème E2C(R2)","en":"Guidance Document - Periodic Benefit-Risk Evaluation Report (PBRER) International Conference on Harmonisation (ICH) Topic E2C(R2)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document - Periodic Benefit-Risk Evaluation Report (PBRER) International Conference on Harmonisation (ICH) Topic E2C(R2)","language":["en"],"created":"2021-07-07T19:41:38.752842","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/international-conference-harmonisation/efficacy/periodic-benefit-risk-evaluation-report-pbrer-international-conference-harmonisation-topic.html","last_modified":null,"position":0,"revision_id":"d96a27bf-c613-41a6-a362-f5ade79537c2","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"8897d00d-e58b-48ac-876b-5db8a5ba1dcf","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"deed97a6-0e76-4091-9cdd-1f2a9796f007","related_relationship":"","name_translated":{"fr":"Ligne directrice - Rapport périodique d'évaluation des avantages et des risques (RPEAR) International Conference on Harmonisation (ICH) thème E2C(R2)","en":"Guidance Document - Periodic Benefit-Risk Evaluation Report (PBRER) International Conference on Harmonisation (ICH) Topic E2C(R2)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document - Periodic Benefit-Risk Evaluation Report (PBRER) International Conference on Harmonisation (ICH) Topic E2C(R2)","language":["fr"],"created":"2021-07-07T19:41:38.752848","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/international-conference-harmonisation/efficacite/rapport-periodique-evaluation-avantages-risques-rpear-international-conference-harmonisation-theme.html#a1","last_modified":null,"position":1,"revision_id":"d96a27bf-c613-41a6-a362-f5ade79537c2","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2013-09-17 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"8897d00d-e58b-48ac-876b-5db8a5ba1dcf","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The Periodic Benefit-Risk Evaluation Report (PBRER) described in this Guideline is intended to be a common standard for periodic benefit-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the International Conference on Harmonisation (ICH) regions. This Guideline defines the recommended format and content of a PBRER and provides an outline of points to be considered in its preparation and submission.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document - Periodic Benefit-Risk Evaluation Report (PBRER) International Conference on Harmonisation (ICH) Topic E2C(R2)","revision_id":"d96a27bf-c613-41a6-a362-f5ade79537c2"}